Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Immunogenicity of MB02-SP and MB02-DM vs US-Avastin in Healthy Volunteers
NCT04408989Phase 1Completed
- Sponsor
- mAbxience
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pemetrexed in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), breast cancer and 3 more (3 arms), sponsored by mAbxience. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity and Maximum Observed Serum Concentration. Started Jan 2021; status: completed.
02
Drugs
pemetrexed
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)breast cancerrenal cell carcinoma (RCC)ovarian cancer
Beyond the preview
Go deeper on NCT04408989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408989.